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REVIEW
Abstract: Inﬂ  uenza is a disease with global impact that causes enormous morbidity and mor-
tality on an annual basis. It primarily infects the respiratory tract and causes a broad range of 
illness ranging from symptomless infection to fulminant primary viral and secondary bacterial 
pneumonia. The severity of infection depends on both the virus strain and a number of host 
factors, primarily age and the presence of comorbid conditions such as cardiopulmonary disease. 
The mortality and utilization of healthcare resources associated with inﬂ  uenza is concentrated 
in the elderly and those with coexisting disease such as chronic obstructive pulmonary disease 
(COPD). Increasing use of vaccination and the development of new antiviral drugs hold out 
hope that the burden of disease associated with inﬂ  uenza can be reduced. However the constant 
emergence of new inﬂ  uenza strains and the current risk of avian inﬂ  uenza pandemic serve as 
warnings that inﬂ  uenza will remain a serious pathogen for the foreseeable future. 
Keywords: COPD, inﬂ  uenza, exacerbations.
Introduction
Viral infections of the respiratory tract are the commonest disease syndrome in 
humans. A number of different viruses can infect the human respiratory tract. Most 
of them cause self-limiting illnesses such as the common cold or acute bronchitis. 
The severity of illness depends on the particular virus and on host factors. In pa-
tients with airway diseases such as chronic obstructive pulmonary disease (COPD), 
the morbidity caused by respiratory virus infection is considerably greater. Among 
respiratory viruses, inﬂ  uenza has the greatest impact in terms of both the morbidity 
and mortality that it causes. Although inﬂ  uenza affects all age groups, much of the 
morbidity and mortality are concentrated in high-risk groups such as the elderly and 
those with comorbid disease, particularly cardiovascular and pulmonary disease. In 
this review we will consider the impact of inﬂ  uenza in one particular high-risk group, 
ie, patients with COPD.
Pathoepidemiology of inﬂ  uenza virus infections
Inﬂ  uenza infections typically occur in both pandemic and interpandemic forms. Pan-
demics occur infrequently and are associated with enormous mortality on a worldwide 
scale whereas epidemic inﬂ  uenza occurs every winter in the temperate zones of the 
northern and southern hemispheres. While less dramatic then the impact of a pan-
demic, epidemic inﬂ  uenza is still the cause of considerable mortality, and as it occurs 
on an annual basis, the total cumulative burden of disease is higher than for the more 
infrequent pandemics. 
Pandemics 
Inﬂ  uenza pandemics are believed to have occurred throughout history with the ﬁ  rst 
recorded documentation of a probable inﬂ  uenza pandemic occurring in the 16th 
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century (Potter 2001). There have been 3 pandemics in 
the 20th century with the last one occurring in 1968. The 
most dramatic pandemic occurred in 1918–1920 caused 
by the H1N1 inﬂ  uenza strain or the so-called ‘Spanish ﬂ  u’. 
Although accurate ﬁ  gures are not available for many parts 
of the world, the pandemic is estimated to have infected 
50% of the world’s population, with 25% suffering a clinical 
infection and to have caused 40–50 million deaths (Palese 
2004). Nearly half of the inﬂ  uenza-related deaths during the 
pandemic occurred among young, healthy adults for reasons 
that remain obscure but are suspected to be related to second-
ary bacterial infection and poor sanitary conditions due to 
the First World War.
A second pandemic occurred in 1957 when a new 
inﬂ  uenza virus H2N2 with two unknown surface proteins 
to which there was little or no pre-existing immune protec-
tion in the human population appeared. The pathogenicity 
of the 1957 strain was less than the one responsible for the 
1918 pandemic and in addition antibiotics were available 
to treat complications such as bacterial pneumonia. Most 
deaths occurred in the very young and very old and estimates 
suggest that 2 million people died (Lipatov et al 2004). In 
1968 another change in the surface glycoproteins led to the 
emergence of a H3N2 strain that again caused the virus to 
become pandemic, resulting in an estimated global excess 
mortality of around 1 million. 
Many scientists believe it is only a matter of time until 
the next influenza pandemic occurs. Fears of a further 
pandemic have been heightened by the emergence of a highly 
pathogenic strain of avian inﬂ  uenza (H5N1) in Asia, and 
the occurrence of cases of transmission of this virus from 
birds to humans. In 1997 this strain of avian inﬂ  uenza virus 
began circulating in poultry populations in Hong Kong and 
was halted only by the slaughter of 1.5 million chickens in 
the territory. Eighteen humans were infected with the virus 
and of these 6 died. From December 2003 to August 2004, 
outbreaks of highly pathogenic avian inﬂ  uenza A occurred 
among poultry in nine countries in Asia (Republic of Korea, 
Vietnam, Japan, Thailand, Cambodia, Laos, Indonesia, 
China, and Malaysia). This was followed by spread to other 
continents with reports of H5N1 inﬂ  uenza in both domestic 
and wild birds from Russia (July 2005), Kazakhstan and 
Mongolia (August 2005), Turkey and Romania (October 
2005), and Africa and Western Europe (February 2006). 
Since the avian inﬂ  uenza outbreak, the main concern has 
been that the virus will either mutate to allow efﬁ  cient 
transmission to mammals, or reassort gene segments with 
human inﬂ  uenza viruses during the coinfection of a single 
host, resulting in a new virus that would be easily transmis-
sible from person to person. Such events are believed to have 
preceded the previous inﬂ  uenza pandemics. To date avian to 
human transmission has occurred in those heavily exposed 
to infected birds, but only isolated cases of human-to-human 
infection have been reported (Normile 2006). As reported 
by the World Health Organization (2006), the total number 
of human cases of avian inﬂ  uenza is 244, with 143 deaths. 
These ﬁ  gures give a mortality rate in humans for this inﬂ  u-
enza strain of 57%, however a recent report has suggested 
that signiﬁ  cant numbers of mild human infections may have 
occurred and therefore the actual mortality rate may be much 
less (Thorson et al 2006).
Epidemics
Annual inﬂ  uenza epidemics occur in the temperate zones 
and are associated with a considerable burden of disease. 
Accurate assessment of the impact of epidemic inﬂ  uenza on 
mortality and morbidity is difﬁ  cult for a number of reasons. 
The symptoms of inﬂ  uenza infection are nonspeciﬁ  c and 
clinically it cannot be distinguished from other respiratory 
viruses such as parainﬂ  uenza virus and respiratory syncytial 
virus (RSV) that circulate at the same time of year. Labora-
tory conﬁ  rmation of inﬂ  uenza virus infection is rarely avail-
able in routine clinical practice. In addition many inﬂ  uenza-
associated deaths occur from secondary complications in 
patients with signiﬁ  cant underlying comorbidity so inﬂ  uenza 
is rarely mentioned as a cause of death on death certiﬁ  cates. 
Consequently the impact of inﬂ  uenza has been determined 
indirectly using statistical models with two approaches com-
monly used. The ﬁ  rst approach calculates excess mortality 
during inﬂ  uenza seasons, excess mortality being deﬁ  ned as 
the sum of deaths during the inﬂ  uenza season that exceeds 
a baseline of expected deaths in the absence of inﬂ  uenza. 
This has the disadvantage that deaths may be due to other 
factors such as other winter viruses and cold temperatures 
that are present at the same time as the inﬂ  uenza season. 
An alternative approach has been to use hospitalization and 
death certiﬁ  cate statistics for pneumonia and inﬂ  uenza, on 
the assumption that the majority of pneumonia is inﬂ  uenza-
related in the inﬂ  uenza season. The downside of this approach 
is that many inﬂ  uenza-related deaths may not be classiﬁ  ed as 
either pneumonia or inﬂ  uenza and so it underestimates the 
total burden of disease attributable to inﬂ  uenza. An American 
study of monthly mortality reports over a 40-year period 
reported excess mortality in four disease classes (pneumonia 
and inﬂ  uenza, ischemic heart disease, cerebrovascular dis-
ease, and diabetes) that accounted for approximately 80% of International Journal of COPD 2007:2(1) 57
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excess all-cause mortality during winter seasons (Reichert 
et al 2004). Seasonal variations have also been noted in the 
incidence of stroke (Lanska and Hoffmann 1999) and an 
association between respiratory tract infection and myocar-
dial infarction reported (Meier et al 1998). Therefore the 
excess mortality associated with influenza is likely to 
extend beyond deaths reported as due to influenza and 
pneumonia only. It has long been recognized that total 
mortality increases markedly during the influenza season 
(Ivan and Duda 1977). Surveillance data from a number 
of countries has shown a strong correlation between the 
incidence of reports of influenza-like illness and death 
rates. Influenza-associated excess mortality in the USA 
in six epidemics from the winters of 1972/73 to 1980/81 
was estimated to be 200,000, with 80%–90% of excess 
mortality occurring in persons over 64 years old (Lui 
and Kendal 1987). Similar data have been obtained from 
other countries. In the UK it is estimated that influenza 
is associated with 12,500 excess deaths per year (Flem-
ing 2000).
More sophisticated models have been used that attempt 
to correct for other factors associated with winter mortality 
to obtain a more accurate picture of inﬂ  uenza-associated 
mortality. A close relation between excess winter-season 
mortality and clinical reports of inﬂ  uenza-like illness has been 
reported that was independent of the effect of temperature 
(Tillett et al 1983). 
A study using national mortality and viral surveillance 
data to estimate annual inﬂ  uenza- and RSV-associated deaths 
in the USA estimated that in the 1990–1991 through 1998–
1999 seasons, inﬂ  uenza alone was associated with an annual 
mean of 8097 pneumonia and inﬂ  uenza deaths (9.8% of these 
deaths). For underlying respiratory and circulatory deaths, 
there was an annual mean of 36,155 inﬂ  uenza-associated 
deaths, (3.1% of these deaths) and for all-cause deaths there 
was an annual mean of 51,203 inﬂ  uenza-associated deaths, 
representing 2.2% of all mortality (Thompson et al 2003). 
This study also found that inﬂ  uenza-associated deaths in the 
USA increased substantially from the 1976–1977 through 
1998–1999 seasons, probably due to the aging of the popu-
lation. Persons in the over 85 age group are 16 times more 
likely to die of an inﬂ  uenza-associated all-cause death than 
persons aged 65 to 69 years (Thompson et al 2003). Other 
studies have also shown that inﬂ  uenza-attributable mortality 
rates increase with age among persons aged 65 years or older 
(Nordin et al 2001), and mortality is higher in those with 
underlying medical conditions such as COPD, congestive 
cardiac failure, and diabetes.
Although the mortality associated with influenza is 
undoubtedly considerable, mortality ﬁ  gures represent only 
a fraction of inﬂ  uenza’s total health burden in a population. 
The effect of inﬂ  uenza on healthcare utilization such as hos-
pitalizations, ofﬁ  ce visits, and medication use in adults has 
been less well documented than the impact on mortality. A 
study of 26 consecutive inﬂ  uenza seasons from 1969–1970 
through 1994–1995, estimated that 3 million excess hospi-
talizations due to pneumonia and inﬂ  uenza occurred in the 
USA (Simonsen et al 2000). Although average rates of excess 
hospitalizations were higher in the elderly (174/100,000 
population) than in those aged <65 years (33/100,000 popula-
tion), the younger age group accounted for more than half 
of the total number of inﬂ  uenza-related hospitalizations. In 
addition, the average number of excess hospitalizations was 
50% higher during seasons when more pathogenic strains 
of influenza A were the predominant circulating virus, 
compared with those dominated by inﬂ  uenza B or milder 
strains of inﬂ  uenza A. The effect of inﬂ  uenza on healthcare 
utilization and medication use was assessed in a study of 
respiratory illnesses in cohorts of healthy elderly patients 
(65 years of age) and high-risk adults (those with chronic 
heart or lung disease) over 4 consecutive winters. Among 
the healthy adults, 42% of those with a conﬁ  rmed inﬂ  uenza 
infection required an ofﬁ  ce visit, 8% an emergency room 
visit, and 33% an antibiotic. In the high-risk group the cor-
responding ﬁ  gures were 60%, 10%, and 60% respectively. 
Twenty percent required hospitalization (Falsey et al 2005). 
These ﬁ  gures reﬂ  ect the greater impact of inﬂ  uenza in high-
risk groups, which includes patients with COPD.
Virology
Inﬂ  uenza viruses are negative stranded, segmented, envel-
oped RNA viruses belonging to the Orthomyxoviridae family 
and 3 virus types: A, B, and C exist. Inﬂ  uenza A and B are the 
main human pathogens whereas inﬂ  uenza C is rarely patho-
genic for man and has no animal reservoir. Virus particles 
consist of three major components: the viral envelope, the 
matrix protein (M1), and the viral ribonucleocapsid. Three 
transmembrane envelope proteins: hemagglutinin (HA), 
neuraminidase (NA), and M2 are anchored in the lipid bilayer 
of the viral envelope. HA provides the receptor-binding site 
and elicits neutralizing antibodies. Cleavage of HA is essen-
tial for fusion and virus infectivity. NA removes the cell sur-
face receptor (sialic acid) and is critical for the release of virus 
particles from the cell surface and spread of virus. M2 is a 
minor protein component of the viral envelope that functions 
as an ion channel crucial during uncoating. Inﬂ  uenza viruses International Journal of COPD 2007:2(1) 58
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are further classiﬁ  ed into subtypes depending on the arrange-
ments of the HA and NA surface glycoproteins. To date 16 
HA subtypes (H1–H16) and 9 NA subtypes (N1–N9) have 
been identiﬁ  ed. Human inﬂ  uenza viruses are limited to three 
HA (H1, H2, and H3) and two NA (N1 and N2) subtypes, 
whereas birds are the predominant hosts for the other subtype 
strains. Variations in these surface glycoproteins mean that 
new antigenic strains of inﬂ  uenza are continually appear-
ing and account for the occurrence of yearly epidemics and 
pandemics. Variation can arise through the two processes 
of antigenic drift and antigenic shift. Antigenic drift occurs 
in both inﬂ  uenza A and B and involves the accumulation 
of point mutations in the surface glycoproteins, leading to 
the evolution of new strains of virus. The new strains are 
related to those circulating during preceding epidemics, but 
once evolved far enough away from preceding strains, the 
virus evades immune recognition which leads to repeated 
outbreaks. Antigenic shift occurs when mixed infection in 
animal hosts allows mixing of genes between different sub-
types and therefore occurs with inﬂ  uenza A only, as B has 
no animal host. This process can result in major changes in 
the surface glycoproteins and emergence of a virus that is 
antigenically distinct from previous human viruses, allowing 
escape from herd immunity. As pigs can be infected with 
both human and avian inﬂ  uenza viruses, it is believed that 
this may be the source of new virus subtypes derived by 
antigenic shift. This can also occur in humans exposed to 
high levels of avian ﬂ  u, or by gradual adaptation of an avian 
strain through repeated minor ‘forays’ into humans before it 
ﬁ  nally adapts sufﬁ  ciently to ‘take off’. Antigenic shift is the 
process underlying the occurrence of inﬂ  uenza pandemics in 
human populations. Human inﬂ  uenza A viruses in the ﬁ  rst 
half of this century carried H1N1 surface antigens but in 1957 
the virus acquired the genes for the H2 and N2 antigens by 
reassortment of its genome with an avian virus. As the human 
population had no immunity to these new antigens the virus 
caused the ‘Asian ﬂ  u’ pandemic. A similar antigenic shift 
gave rise to the H3N2 virus and the pandemic of 1968. The 
arrangement of the membrane proteins also inﬂ  uences the 
virulence of inﬂ  uenza strains. The H3N2 strain of inﬂ  uenza 
A is the most virulent of the recently circulating inﬂ  uenza 
viruses and the predominance of this strain during the 1990s 
may have been another important factor contributing to the 
increase in inﬂ  uenza-associated deaths.
Inﬂ  uenza and COPD
Chronic obstructive pulmonary disease affects an estimated 
600,000 people in the UK and accounts for 30,000 deaths per 
year. In the USA it is estimated to affect 24 million people 
and is the 4th leading cause of morbidity and mortality (Ren-
nard et al 2002). On a worldwide basis, it is estimated that 
COPD will be the 3rd leading cause of mortality by the year 
2020 (Murray and Lopez 1997). Much of the morbidity and 
mortality associated with COPD are due to acute exacerba-
tions. In the USA, COPD is responsible for an estimated 1.4 
million emergency department visits and almost 662,000 hos-
pitalizations (1.9% of total hospitalizations). An additional 
2.5 million hospitalizations (7.0% of total hospitalizations) 
had COPD listed as a contributing cause. However the bur-
den of disease of COPD is proportionately even greater in 
the elderly. In patients aged 65 to 75 years and 75 years, 
COPD was a primary or contributing cause of hospitalization 
in 19.9%, and 18.2%, respectively, of total hospitalizations 
(Mannino 2002). In the USA, 64% of the direct costs of 
COPD are accounted for by hospitalizations and emergency 
room visits (Sullivan et al 2000). In the UK, exacerbations 
are the largest single cause of acute respiratory admissions. 
In 2003 there were almost 100,000 hospital admissions for 
acute exacerbations of COPD with a mean hospital stay of 
10 days resulting in almost 1,000,000 bed days (Donaldson 
and Wedzicha 2006).
Exacerbations can be caused by a number of factors 
but the commonest cause is infection of the tracheo-
bronchial tree. Historically COPD exacerbations have been 
considered as being predominantly caused by bacteria, 
however recent evidence has suggested that respiratory 
viruses are associated with 40%–60% of COPD exacerba-
tions (Seemungal et al 2001; Rohde et al 2003; Tan et al 
2003). There is little evidence published to date regarding 
the speciﬁ  c role of inﬂ  uenza virus infection in COPD, but 
studies of inﬂ  uenza in patients with a nonspeciﬁ  c diagno-
sis of chronic lung disease have provided evidence of the 
impact of inﬂ  uenza in COPD.  
Indirect studies of inﬂ  uenza in COPD 
exacerbations
Much of the evidence of an association between inﬂ  uenza 
infection and adverse outcomes in COPD is derived from 
studies of influenza in the elderly and in patients with 
chronic lung diseases. These studies include patients with a 
number of diagnoses, including asthma and bronchiectasis, 
so the results cannot be extrapolated to COPD alone. Many 
of these studies have had the primary aim of evaluating the 
efﬁ  cacy of inﬂ  uenza vaccination but the outcome measures 
in the nonvaccinated group provide valuable data on the International Journal of COPD 2007:2(1) 59
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impact of inﬂ  uenza in COPD. Among patients hospitalized 
with acute respiratory disease during an inﬂ  uenza epidemic 
chronic pulmonary disease is the most common underlying 
disease (Glezen et al 1987), suggesting that pulmonary dis-
ease including COPD is the most important risk factor for 
an adverse outcome with inﬂ  uenza infection. 
A US study used viral surveillance to evaluate the con-
tribution of inﬂ  uenza to rates of hospitalization, mortality, 
outpatient visits, and antibiotic courses among those enrolled 
in Medicaid over 4 years. Among patients with chronic lung 
disease there were an estimated 13 and 23 excess hospitaliza-
tions per 1000 persons per year due to inﬂ  uenza in the age 
groups 50 to 64, and 65 years or older, respectively. Among 
those with chronic lung disease 65 years or older, there were 
23.8 (95% conﬁ  dence interval [CI], 10.1–37.5) deaths due 
to inﬂ  uenza per 10,000 persons. The estimated increase in 
antibiotic prescriptions attributed to inﬂ  uenza ranged from 
64 to 108 prescriptions per 1000 persons with chronic lung 
disease. Inﬂ  uenza virus and RSV together accounted for 
9% of deaths in those 65 years or older (Grifﬁ  n et al 2002). 
Another study of adults aged 65 with a diagnosis of chronic 
lung disease enrolled in a health maintenance organization 
found that among those not vaccinated for inﬂ  uenza the rate 
of hospitalization for pneumonia and inﬂ  uenza doubled from 
55 per 1000 person years during the noninﬂ  uenza season to 
110 hospitalizations per 1000 person-years during the inﬂ  u-
enza season (Nichol et al 1999). A study from Hong Kong 
estimated the excess of hospital admissions attributable to 
inﬂ  uenza in patients over 65 years with cardiorespiratory 
disease, but differentiated COPD from asthma. Inﬂ  uenza 
activity was an independent signiﬁ  cant factor affecting hos-
pital admission rates for COPD but not for asthma (Yap et al 
2004). This would suggest that in this age group the impact of 
inﬂ  uenza in patients with chronic respiratory disease occurs 
predominantly in COPD patients. 
Direct studies of Inﬂ  uenza in COPD 
exacerbations
Older studies of the role of respiratory viruses in COPD exac-
erbations suggested that they are responsible for a minority of 
exacerbations only, with viruses detected in 18% of episodes 
of acute respiratory illness (Smith et al 1980). However more 
recent studies using modern diagnostic methods such as 
polymerase chain reaction (PCR) have achieved much higher 
viral detection rates and the association of virus infections 
with COPD is much higher than previously suspected. The 
ﬁ  rst report using PCR detected a virus in 39% of COPD 
exacerbations in a cohort of patients with moderate to severe 
COPD (Seemungal et al 2001). The most common viruses 
detected were rhinoviruses (58% of viruses) and inﬂ  uenza 
was detected in 16% of virus-associated exacerbations. 64% 
of the exacerbations were preceded by colds so the propor-
tion of virus-associated exacerbations may be even higher 
than the 39% virus detection rate. Seventy-four percent 
of study patients had received inﬂ  uenza vaccination. In 
a study from Germany of more severe exacerbations that 
resulted in hospitalization, viruses were detected in 56% 
of exacerbations, compared with an detection rate of 19% 
in a control group with stable COPD (Rohde et al 2003). 
Again picornaviruses were the most common virus detected, 
accounting for 36% of viruses detected, and inﬂ  uenza was 
detected in 25% of exacerbations. In 14 patients hospitalized 
with an acute exacerbation of COPD in Singapore a virus 
was detected in 64% of patients (Tan et al 2003). In this 
study the commonest virus detected was inﬂ  uenza (36%), 
but patients had not received inﬂ  uenza vaccination. A study 
from the USA of a mixture of exacerbations treated both 
as inpatients and outpatients detected a respiratory virus in 
41.8% of exacerbations. However this was likely an under-
estimate as in some of the patients PCR was not used for 
virus detection. Inﬂ  uenza viruses were detected in 8.2% of 
exacerbations (Beckham et al 2005). In a study of inﬂ  uenza 
vaccination in COPD patients, inﬂ  uenza accounted for 16% 
of all cases of acute respiratory illness during the winter 
season (Neuzil et al 2003).
These studies have focused solely on the role of virus 
infection. However, bacterial infection is common in 
COPD both at exacerbation and in stable disease. There 
is epidemiological and experimental evidence that viral 
respiratory infections, particularly those caused by 
influenza virus, increase the incidence of secondary 
bacterial infection such as pneumonia. Therefore there 
is potential for significant virus–bacteria interaction in 
COPD but little data is available regarding this. A study 
using serological evidence of virus infection did report 
a significant association between influenza infection 
and infection with both Streptococcus pneumoniae and 
Haemophilus influenzae (Smith et al 1976). A more 
recent study using PCR detected a viral infection in 48% 
of exacerbations in a population of COPD patients (Papi 
et al 2006). Consistent with other published studies rhi-
novirus infections were the most common and influenza 
was second, accounting for 23% of virus-associated ex-
acerbations. In 25% of exacerbations there was evidence 
of co-infection with a virus and bacteria and these were International Journal of COPD 2007:2(1) 60
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associated with greater impairment in lung function and 
longer hospitalization.
Avian inﬂ  uenza and COPD
To date most human infections with the H5N1 avian inﬂ  uenza 
strain have occurred in young adults and children. If spread 
to the wider population does occur it remains unknown what 
the impact of this inﬂ  uenza virus will be in the elderly and 
those with chronic cardiorespiratory diseases such as COPD. 
Mortality in the 1918 pandemic was greater in young adults, 
but the proportion of the population who were elderly or 
had chronic diseases would have been much lower than 
the present. The mortality and morbidity of epidemic 
influenza is greater among these groups and therefore 
avian influenza has the potential to impose an enormous 
strain on healthcare resources. Recent studies have also 
re-evaluated the role of bacterial infection in the 1918 
pandemic. It is now thought that much of the mortality 
may have been due to bacterial pneumonia with organisms 
such as S. pneumonia and H. influenzae, rather than pri-
mary viral pneumonia (Brundage 2006). These organisms 
are common colonizing organisms in COPD patients. In 
addition the mortality and requirement for intensive care 
of community acquired bacterial pneumonia is higher in 
COPD patients (Restrepo et al 2006). Therefore there 
is considerable potential for high mortality and mortal-
ity in COPD patients in the event of an avian influenza 
pandemic. To date planning for a pandemic has focused 
on stockpiling antiviral drugs. A better understanding 
of the potential impact of avian influenza infection in 
high-risk groups such as the elderly and COPD patients 
is urgently required. This will allow planning of other 
healthcare resources such as vaccination, antibiotics, 
intensive care beds, and assisted ventilation that may 
have an impact on the morbidity and mortality associated 
with such a pandemic.
Management options
The current options for prevention and treatment of inﬂ  uenza 
are among the most advanced for any respiratory virus. Vac-
cination is the cornerstone of attempts to control inﬂ  uenza, 
however the frequent changes in viral antigens means that 
annual re-vaccination is required. Vaccination does not result 
in complete protection and therefore there is still a role for 
drug therapy. The determination of the molecular structure 
of the inﬂ  uenza virus has led to the identiﬁ  cation of the key 
proteins involved in viral replication and subsequently the 
development of drugs to target these. 
Vaccination
Inﬂ  uenza vaccination has proved to be efﬁ  cacious and safe 
and currently represents the mainstay for inﬂ  uenza preven-
tion. Because of the constantly changing antigenic make-up 
of the virus, vaccination must be repeated on an annual basis 
to cover the predominant virus strains circulating in the com-
munity. Each year the World Health Organization (WHO) 
Global Inﬂ  uenza Program recommends the composition of 
the inﬂ  uenza vaccine for the next season based on surveil-
lance data from a worldwide network of national inﬂ  uenza 
centers and WHO collaborating centers. There is now 
extensive evidence that vaccination reduces the incidence 
of adverse outcomes associated with inﬂ  uenza. However 
debate continues regarding the extent of this protection and 
the populations that should receive vaccination. The devel-
opment of antibodies directed against the hemagglutinin and 
neuraminidase glycoproteins are associated with protection 
against infection and amelioration of illness. Both inacti-
vated and live virus vaccines are available. Most inﬂ  uenza 
vaccines are either split vaccines that are produced from the 
disrupted highly puriﬁ  ed inﬂ  uenza virus, or surface antigen 
vaccines containing predominantly puriﬁ  ed hemagglutinin 
and neuraminidase. Most inactivated vaccines are trivalent, 
containing two inﬂ  uenza A subtypes (H1N1 and H3N2) and 
one inﬂ  uenza B strain and following vaccination 90% of 
subjects achieve serum hemagglutinin-inhibition titres of 
>1:40, a level generally associated with protection of about 
50% of the population. 
Vaccination and COPD
A number of international and national respiratory socie-
ties have published guidelines for the optimal management 
of COPD (Pauwels et al 2001; Celli et al 2004). These 
guidelines universally recommend annual inﬂ  uenza vac-
cination but there is actually very little evidence regarding 
the efﬁ  cacy of vaccination speciﬁ  cally in COPD patients. A 
Cochrane systematic review of randomized controlled trials 
that have been reported on the effects of inﬂ  uenza vaccina-
tion in COPD identiﬁ  ed 11 papers (Poole et al 2006). Of 
these, 3 studies were performed on subjects with chronic 
bronchitis and only 3 enrolled subjects solely with docu-
mented COPD. The other 5 trials included were conducted 
in subjects of whom a proportion, varying from 5% to 32%, 
had chronic lung disease. Where possible, data from the lung 
disease subgroup were included but in none of these studies 
was it possible to ascertain what proportion of the chronic 
lung disease subgroup had COPD. Of the 3 trials in COPD 
patients only 1 was a placebo-controlled trial whereas the International Journal of COPD 2007:2(1) 61
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other 2 compared the effect of different inﬂ  uenza vaccination 
regimes. Based mainly on data from one old study in patients 
with chronic bronchitis (Howells and Tyler 1961) and one 
recent study in COPD (Wongsurakiat et al 2004) inﬂ  uenza 
vaccination did reduce exacerbation rates in COPD patients, 
but there was no evidence of any effect on hospitalization 
rates and mortality. In the study in COPD patients, none 
of the vaccinated patients required mechanical ventilation 
because of inﬂ  uenza-related respiratory illness, whereas all 
the unvaccinated patients with moderate-to-severe COPD 
who were hospitalized because of inﬂ  uenza-related respi-
ratory illness needed mechanical ventilation. However the 
reduction in the numbers of hospitalizations and need for 
mechanical ventilation did not reach statistical signiﬁ  cance 
(Wongsurakiat et al 2004). 
Indirect evidence of a beneﬁ  t of vaccination in COPD 
patients has come from studies in patients with nonspeciﬁ  c 
chronic pulmonary disease. These studies have provided evi-
dence that inﬂ  uenza vaccination reduces both hospitalizations 
and mortality. A study of persons over 65 years and older with 
chronic lung disease found that inﬂ  uenza vaccination was 
associated with a 52% reduction in hospitalization rate for 
inﬂ  uenza and pneumonia and a 70% reduction in mortality. 
Vaccination was also associated with fewer outpatient visits 
for all respiratory conditions (Nichol et al 1999). Other 
studies of high-risk groups that included patients with both 
cardiac and pulmonary disease have had similar ﬁ  ndings 
(Nichol et al 1994, 1998).
The evidence base is not large despite the universal 
recommendation that COPD patients receive inﬂ  uenza vac-
cination. The evidence that is available does suggest that 
vaccination reduces exacerbations and studies in elderly 
patients with chronic lung disease (a high proportion of whom 
can be assumed to have COPD) would favor a reduction in 
mortality with vaccination. In view of this it is unlikely that 
further placebo-controlled trials of inﬂ  uenza vaccination will 
be carried out. Despite the expert recommendations there is 
evidence that inﬂ  uenza vaccination among COPD patients 
remains suboptimal (Garcia-Aymerich et al. 2000) and every 
effort should be made to increase uptake of vaccination in 
this high-risk population.
Drug treatments
Even where uptake of vaccine is high, inﬂ  uenza outbreaks 
with associated complications and mortality continue to 
occur (Bowles et al 2002). Therefore alternative management 
options for inﬂ  uenza are required and a number of antiviral 
drugs are available for the treatment of inﬂ  uenza. 
M2 Inhibitors
M2 is a membrane protein found in inﬂ  uenza A but not 
inﬂ  uenza B that is required for nucleocapsid release after 
viral fusion. Two compounds are available that inhibit func-
tion of the M2 protein and prevent viral uncoating following 
endocytosis. In the USA, both amantadine and rimantadine 
are licensed for the treatment and prophylaxis of inﬂ  uenza 
A infections, whereas in the UK only amantidine is licensed. 
A number of clinical studies assessing the efﬁ  cacy of the 
M2 inhibitors have been published. A Cochrane review 
published in 2004 (Jefferson et al 2004) and a more recent 
systematic review (Jefferson et al 2006) have analyzed the 
results of these trials. Both amantadine and rimantadine are 
effective at preventing inﬂ  uenza when used as prophylaxis, 
with efﬁ  cacy rates of 61% and 72% respectively. When used 
to treat established inﬂ  uenza both drugs reduce the duration 
of fever and symptoms in patients by 24-h, when started 
within 48-h of onset of illness. However their effectiveness 
(the capacity to prevent inﬂ  uenza) is much less than their 
efﬁ  cacy (the ability to prevent inﬂ  uenza-like illnesses). 
Neither drug has an effect on reducing viral shedding. Side 
effects are common with the adamantanes and are a major 
limiting factor in their use. Side effects involving the central 
nervous system occur in 5%–29% of patients treated with 
amantadine, and include headache, light-headedness, diz-
ziness, difﬁ  culty in concentrating, and insomnia. Central 
nervous system adverse effects and withdrawal from trials 
are signiﬁ  cantly more common among amantadine recipients 
than rimantadine recipients. There are no trials of M2 inhibi-
tors in COPD patients; therefore their effectiveness in this 
population group is unknown. 
Another signiﬁ  cant concern with the M2 inhibitors is the 
high frequency of resistance to these drugs in H3N2 inﬂ  uenza 
(Bright et al 2005). A recent report detected increasing inci-
dence of H3N2 viruses with a particular M2 protein mutation 
that confers high-level resistance to both amantadine and 
rimantadine from countries participating in WHO’s global 
influenza surveillance network. Adamantane resistance 
increased in frequency from 0.4% of inﬂ  uenza A viruses 
isolated in 1994–1995 to 12.3% in 2003–2004. Resistant 
strains were detected in a wide range of geographical sites, 
but 61% of resistant viruses isolated since 2003 originated 
from Asia. If resistance continues to increase at this rate the 
M2 inhibitors will have little efﬁ  cacy as anti-inﬂ  uenza agents. 
Of concern is the fact that the currently circulating strains 
of avian H5N1 inﬂ  uenza are highly resistant, thus if human 
infections do become more frequent, the M2 inhibitors will 
have no useful therapeutic roleInternational Journal of COPD 2007:2(1) 62
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Neuraminidase inhibitors
Neuraminidase is an enzyme expressed on the surface of in-
ﬂ  uenza A and B that is essential for release of newly formed 
viruses from an infected cell. NA cleaves the cellular-receptor 
sialic acid residues to which the newly formed viral particles 
are attached, releasing the viruses to invade new cells. Neu-
raminidase may also cleave the sialic acid moieties on airway 
mucin, facilitating viral invasion of airway epithelial cells. 
Inhibition of NA therefore limits infection to one round of 
replication, greatly reducing viral reproduction. The active 
site of NA is a highly conserved region among inﬂ  uenza A 
and B viruses and determination of its 3 dimensional structure 
led to the development of compounds capable of binding to 
and inhibiting the active catalytic site (Colman et al 1983). 
There are two licensed neuraminidase inhibitors, zanamivir 
and oseltamivir, and a third, RWJ-270201 which is in Phase 
II clinical studies. All three compounds are highly active 
against a broad range of inﬂ  uenza A and B viruses and 
also inhibit amantadine and rimantadine resistant strains of 
inﬂ  uenza A.
Zanamivir has a low oral bioavailability and so is 
delivered in inhaled form whereas oseltamivir is available 
orally. Studies of zanamivir in inﬂ  uenza have shown that it 
reduces symptoms by 24-h, decreases the number of nights 
of disturbed sleep, and reduces use of over the counter medi-
cations. There is little data available regarding the efﬁ  cacy 
of zanamivir speciﬁ  cally in COPD. There is one study of 
zanamivir in patients with respiratory disease that included 
patients with both asthma and COPD (Murphy et al 2000). In 
the inﬂ  uenza-positive population (313 patients) the median 
time to alleviation of inﬂ  uenza symptoms was signiﬁ  cantly 
shorter by 1.5 days (95% CI 0.50 to 3.25 days, p = 0.009) 
in the zanamivir group compared with placebo. In addition, 
there was a signiﬁ  cant reduction in the mean total symptom 
score (p = 0.001) in zanamivir-treated patients compared with 
placebo during the treatment period (days 1 to 5). Inﬂ  uenza-
related complications requiring both the use of antibiotics 
and a change in respiratory medication were reduced by 
58% (relative risk 0.42, 95% CI 0.18 to 0.96; p = 0.064) with 
zanamivir treatment compared with placebo. Patients treated 
with zanamivir had a small but signiﬁ  cantly increased mean 
peak expiratory ﬂ  ow rate compared with placebo during the 
treatment period. The only data quoted in the study that was 
speciﬁ  c to the COPD group was for alleviation of symptoms. 
In 64 patients with COPD the median time to alleviation of 
symptoms was shorter by 1.5 days in the zanamivir group 
(6.0 days) compared with placebo (7.5 days). A retrospective 
analysis of ‘high-risk’ patients (mainly patients with chronic 
respiratory disease) enrolled in trials of zanamivir found that 
the beneﬁ  t is even greater in these patient groups (Lalezari 
et al 2001). Use of zanamivir in high-risk patients resulted 
in a 2.5-day reduction in time to alleviation of symptoms, 
a 3-day reduction in the time to returning to usual activity 
and a 43% risk reduction in antibiotic use. This study did 
not report a higher incidence of adverse effects in high-risk 
patients treated with zanamivir and the incidence of asthma 
exacerbation or increase in symptoms was 14% in the placebo 
group and 7% in the treatment group. 
Oseltamivir has shown a similar efﬁ  cacy to zanamivir in 
healthy adults and children with reductions in illness sever-
ity and duration, viral shedding, and lower respiratory tract 
complications. An analysis of data from subjects enrolled 
in trials of oseltamivir treatment that included both healthy 
adults and high-risk individuals including COPD has been 
published (Kaiser et al 2003). In adults with a proven inﬂ  u-
enza illness, oseltamivir treatment reduced overall antibiotic 
use and the incidence of inﬂ  uenza-related lower respiratory 
tract complications by 55%. In high-risk individuals there 
was a 34% reduction in lower respiratory tract illness leading 
to antibiotic use. There was also a 50% reduction in hospi-
talizations associated with use of oseltamivir in the high-risk 
group. A randomized, open~label trial in Chinese patients 
with chronic respiratory and cardiac diseases reported that 
oseltamivir signiﬁ  cantly reduced the duration of inﬂ  uenza 
symptoms, the incidence of complications and antibiotic use 
(Lin et al 2006). A study of oseltamivir in asthmatic chil-
dren reported improvements in lung function and reduced 
asthma exacerbations during inﬂ  uenza infection (Johnston 
et al 2005). 
From the currently available evidence it is difﬁ  cult to 
make speciﬁ  c recommendations regarding the treatment of 
inﬂ  uenza in COPD, beyond the universal recommendation 
that COPD patients receive annual inﬂ  uenza vaccination. Tri-
als of NA inhibitors in high-risk patients that have included 
COPD patients have demonstrated beneﬁ  t with reductions 
in symptoms, lower respiratory tract complications, and 
antibiotic use. Further trials are required to more precisely 
determine the role of NA inhibitors in COPD patients. Treat-
ment recommendations will need to address speciﬁ  c clinical 
problems such as their role in vaccinated patients, their use 
where a laboratory diagnosis of inﬂ  uenza is not available, 
and the cost effectiveness of drug treatment. 
Conclusions
Despite much research progress in recent years, inﬂ  uenza 
remains a pathogen associated with considerable morbidity International Journal of COPD 2007:2(1) 63
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and mortality, especially in high-risk groups such as patients 
with COPD. However there has been little research into the 
speciﬁ  c role of inﬂ  uenza in causing acute exacerbations of 
COPD. Vaccination remains an effective measure to reduce 
the burden of disease associated with inﬂ  uenza, but cannot 
completely prevent disease. Effective anti-inﬂ  uenza agents 
are now available but their use is tempered by issues of cost 
and patient selection. Studies of the NA inhibitors have 
shown that their beneﬁ  t is greater in high-risk patients, but 
use of these drugs is not common in COPD. Further research 
is required to determine the most efﬁ  cient and cost-effective 
strategies to combat inﬂ  uenza infection, including studies in 
high-risk groups such as COPD patients in whom the burden 
of disease associated with inﬂ  uenza is greater.
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